HK1208363A1 - New methods - Google Patents
New methodsInfo
- Publication number
- HK1208363A1 HK1208363A1 HK15109093.0A HK15109093A HK1208363A1 HK 1208363 A1 HK1208363 A1 HK 1208363A1 HK 15109093 A HK15109093 A HK 15109093A HK 1208363 A1 HK1208363 A1 HK 1208363A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- new methods
- new
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644268P | 2012-05-08 | 2012-05-08 | |
US201261651778P | 2012-05-25 | 2012-05-25 | |
US201361799606P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/040194 WO2013169939A2 (en) | 2012-05-08 | 2013-05-08 | New methods |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208363A1 true HK1208363A1 (en) | 2016-03-04 |
Family
ID=49551452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109093.0A HK1208363A1 (en) | 2012-05-08 | 2015-09-17 | New methods |
Country Status (14)
Country | Link |
---|---|
US (4) | US9994514B2 (ja) |
EP (1) | EP2846787B1 (ja) |
JP (2) | JP6238969B2 (ja) |
KR (1) | KR102200176B1 (ja) |
CN (2) | CN104602682B (ja) |
AU (2) | AU2013259526B2 (ja) |
BR (1) | BR112014027983B1 (ja) |
CA (1) | CA2872012C (ja) |
ES (1) | ES2699646T3 (ja) |
HK (1) | HK1208363A1 (ja) |
IL (1) | IL235512B (ja) |
MX (1) | MX363473B (ja) |
RU (1) | RU2671495C2 (ja) |
WO (1) | WO2013169939A2 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
WO2015069961A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel prodrug salts |
US20180042873A1 (en) * | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
JP2018500388A (ja) * | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
CZ305738B6 (cs) * | 2014-12-16 | 2016-02-24 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující |
US10246733B2 (en) | 2015-06-04 | 2019-04-02 | Case Western University | Assay and method for quantitating carbonic anhydrase activity and assessing red blood hemolysis |
CN105030747B (zh) * | 2015-07-03 | 2017-11-17 | 厦门大学 | 氯硝柳胺在制备防治近视药物中的应用 |
PE20181295A1 (es) | 2015-09-01 | 2018-08-07 | First Wave Bio Inc | Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala |
RU2018144043A (ru) * | 2016-05-13 | 2020-06-15 | Аэромикс, Инк. | Кристаллы |
WO2017201313A1 (en) | 2016-05-18 | 2017-11-23 | Shengkan Jin | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
WO2018053807A1 (zh) * | 2016-09-23 | 2018-03-29 | 深圳市中医院 | 氯硝柳胺乙醇胺盐在制备1型糖尿病药物中的应用 |
TWI631944B (zh) * | 2016-10-14 | 2018-08-11 | 長庚大學 | 氯硝柳胺及其衍生物的用途 |
EP3624885A4 (en) | 2017-05-19 | 2021-03-10 | Trudell Medical International | POSITIVE EXPIRATORY PRESSURE DEVICE |
JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α1−アンチキモトリプシンを含むバイオマーカー |
US10945995B2 (en) * | 2017-09-26 | 2021-03-16 | Deha, Llc | Compositions and methods for channelopathy disorders-targeting fluid movement across membranes |
CN108203719A (zh) * | 2017-12-26 | 2018-06-26 | 吉林医药学院 | 用于治疗视神经脊髓炎的小分子化合物及其高通量筛选方法 |
USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
USD902947S1 (en) * | 2019-03-25 | 2020-11-24 | Apple Inc. | Electronic device with graphical user interface |
CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
CN110790787B (zh) * | 2019-11-12 | 2022-06-14 | 广东药科大学 | 一类水溶性前药、其制备方法及其作为药物的用途 |
US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
CN117337182A (zh) * | 2020-08-05 | 2024-01-02 | 江苏先声药业有限公司 | 一种水通道蛋白抑制剂的药物组合物及其制备方法 |
CN116139116A (zh) * | 2023-03-30 | 2023-05-23 | 中南大学湘雅医院 | 氯硝柳胺在抑制急性肝衰竭中的应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE615511A (ja) | 1961-03-25 | |||
NL292958A (ja) | 1962-05-29 | 1900-01-01 | ||
GB8809205D0 (en) | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
US5137871A (en) * | 1989-07-28 | 1992-08-11 | Regents Of The University Of California | Treatment to reduce edema for brain and musculature injuries |
DE4010536A1 (de) | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
US5137817A (en) | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
DE4113820A1 (de) | 1991-04-27 | 1992-10-29 | Boehringer Mannheim Gmbh | Verwendung von torasemid zur behandlung von hirnoedemen |
US5486530A (en) | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
US5858702A (en) | 1991-12-13 | 1999-01-12 | The Johns Hopkins University | Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5) |
US5741671A (en) | 1991-12-12 | 1998-04-21 | The Johns Hopkins University | Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1) |
US5519035A (en) * | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
US20060167110A1 (en) * | 1995-01-13 | 2006-07-27 | Blume Cherly D | Methods for treating cerebrovascular disease by administering desmethylselegiline |
WO1998021951A1 (en) | 1996-11-18 | 1998-05-28 | Emisphere Technologies, Inc. | Methods and compositions for inducing oral tolerance in mammals |
WO1999007382A1 (en) | 1997-08-06 | 1999-02-18 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases |
US5905090A (en) * | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
US6500809B1 (en) * | 1999-11-12 | 2002-12-31 | Neuron Therapeutics, Inc. | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
ES2211460T3 (es) * | 1999-12-10 | 2004-07-16 | Pfizer Inc. | Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina. |
UA82827C2 (en) * | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
AU2003222020B2 (en) | 2002-03-20 | 2008-08-28 | University Of Maryland Baltimore | A non-selective cation channel in neural cells and methods for treating brain swelling |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
CN1658854A (zh) | 2002-06-05 | 2005-08-24 | 株式会社医药分子设计研究所 | 免疫关联蛋白激酶抑制剂 |
CA2487891A1 (en) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
JP4743382B2 (ja) | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | O−置換ヒドロキシアリール誘導体 |
CA2488367A1 (en) | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
US20060089395A1 (en) * | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
CA2488974A1 (en) | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
EA011707B1 (ru) | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
KR20050019739A (ko) * | 2002-06-11 | 2005-03-03 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 신경변성질환 치료제 |
CN1681487A (zh) | 2002-07-15 | 2005-10-12 | 美瑞德生物工程公司 | 化合物、组合物及其使用方法 |
WO2004068928A2 (en) | 2003-02-06 | 2004-08-19 | Uutech Limited | Bradykinin b2 receptor antagonist peptide from amphibian skin |
DE602004002585T2 (de) * | 2003-05-01 | 2007-10-25 | Innogene Kalbiotech Pte. Ltd. | Laktathaltige pharmazeutische Zusammensetzung und deren Verwendungen |
CN100406006C (zh) | 2003-07-16 | 2008-07-30 | 株式会社医药分子设计研究所 | 皮肤色素沉着的治疗剂 |
CN1886393A (zh) | 2003-10-08 | 2006-12-27 | 沃泰克斯药物股份有限公司 | 含有环烷基或吡喃基基团的atp-结合弹夹转运蛋白的调控剂 |
US8467876B2 (en) * | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
WO2005039556A1 (ja) | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | 血行再建術後の再狭窄又は再閉塞の治療及び/又は予防のための医薬 |
EP1691817A2 (en) | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
ATE486606T1 (de) | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür |
US7601745B2 (en) * | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
WO2006074127A2 (en) | 2005-01-04 | 2006-07-13 | Novartis Ag | Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation |
MY147790A (en) | 2005-04-28 | 2013-01-31 | Takeda Pharmaceutical | Stable emulsion composition |
WO2007084464A2 (en) | 2006-01-17 | 2007-07-26 | The University Of North Carolina At Chapel Hill | Water channel blockers and methods of use thereof |
JP4273235B2 (ja) | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン4阻害薬 |
KR20090027227A (ko) | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-dll4 항체 및 이의 사용 방법 |
WO2007143689A2 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
WO2008052190A2 (en) | 2006-10-26 | 2008-05-02 | Flynn Gary A | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
WO2008067196A2 (en) | 2006-11-16 | 2008-06-05 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
US20080171719A1 (en) | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
US20080214486A1 (en) | 2006-11-28 | 2008-09-04 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONS |
CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
US20120183600A1 (en) | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
CA2675638C (en) * | 2007-01-16 | 2015-11-24 | Ipintl, Llc | Composition comprising serotonin for treating metabolic syndrome |
US20100092469A1 (en) | 2007-02-09 | 2010-04-15 | Simard J Marc | Antagonists of a non-selective cation channel in neural cells |
EP2124539A2 (en) | 2007-02-17 | 2009-12-02 | President and Fellows of Harvard College | Compositions and method for tissue preservation |
WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
EP2178531A4 (en) | 2007-07-02 | 2012-01-11 | Yu Ming | METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS |
US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
AU2008314979A1 (en) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Inhibitor of PAI-1 production |
US8277845B2 (en) | 2007-12-04 | 2012-10-02 | Remedy Pharmaceuticals, Inc. | Formulations and methods for lyophilization and lyophilates provided thereby |
GB0724340D0 (en) | 2007-12-13 | 2008-01-30 | Univ Dundee | Novel Therapeutic Agents |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
US8211882B2 (en) | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
WO2009139925A1 (en) * | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
WO2010033560A2 (en) | 2008-09-16 | 2010-03-25 | University Of Maryland, Baltimore | Sur1 inhibitors for therapy |
WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
GB0823366D0 (en) | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
WO2010079406A1 (en) * | 2009-01-12 | 2010-07-15 | Purapharm International (Hk) Limited | Compounds and uses thereof for treating inflammation and modulating immune responses |
US20120039805A1 (en) * | 2009-02-20 | 2012-02-16 | Pangea Biosciences, Inc. | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
RU2564900C2 (ru) * | 2010-03-10 | 2015-10-10 | Дзе Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. | Модулирование аквапоринов релаксином |
CN109172363A (zh) | 2010-07-19 | 2019-01-11 | 比根切萨彼公司 | 静脉内施用格列苯脲和其他药物的方法 |
JP2013535457A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
EP2685972A4 (en) | 2011-03-14 | 2014-08-13 | Io Therapeutics Inc | TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS USING RAR ALPHA SELECTIVE AGONISTS |
EP2717883B1 (en) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
RU2461375C1 (ru) | 2011-05-19 | 2012-09-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ комбинированного лечения больных местно-распространенным раком желудка |
WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
EP2844345B1 (en) | 2012-05-04 | 2022-08-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Modulators of the relaxin receptor 1 |
WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
WO2015037659A1 (ja) | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | 水溶液製剤及びその製造方法 |
WO2015069961A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Llc | Novel prodrug salts |
DK3080134T3 (en) | 2013-12-13 | 2018-10-22 | Vertex Pharma | PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS |
US20180042873A1 (en) | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
ES2927482T3 (es) | 2015-05-29 | 2022-11-07 | Univ Maryland | Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales |
ES2940669T3 (es) | 2015-10-07 | 2023-05-10 | Biogen Chesapeake Llc | Métodos de tratamiento de lesiones o afecciones relacionadas con edema del SNC |
RU2018144043A (ru) | 2016-05-13 | 2020-06-15 | Аэромикс, Инк. | Кристаллы |
CN109689037B (zh) | 2016-07-29 | 2022-09-13 | 生物切萨皮克有限责任公司 | 利用sur1-trpm4通道抑制剂的医学治疗方法 |
CN117337182A (zh) | 2020-08-05 | 2024-01-02 | 江苏先声药业有限公司 | 一种水通道蛋白抑制剂的药物组合物及其制备方法 |
-
2013
- 2013-05-08 WO PCT/US2013/040194 patent/WO2013169939A2/en active Application Filing
- 2013-05-08 CN CN201380033198.7A patent/CN104602682B/zh active Active
- 2013-05-08 CN CN201811415090.5A patent/CN109512805B/zh active Active
- 2013-05-08 JP JP2015511669A patent/JP6238969B2/ja active Active
- 2013-05-08 KR KR1020147033957A patent/KR102200176B1/ko active IP Right Grant
- 2013-05-08 RU RU2014148984A patent/RU2671495C2/ru active
- 2013-05-08 MX MX2014013639A patent/MX363473B/es unknown
- 2013-05-08 BR BR112014027983-7A patent/BR112014027983B1/pt active IP Right Grant
- 2013-05-08 AU AU2013259526A patent/AU2013259526B2/en active Active
- 2013-05-08 CA CA2872012A patent/CA2872012C/en active Active
- 2013-05-08 US US14/398,947 patent/US9994514B2/en active Active
- 2013-05-08 EP EP13788050.6A patent/EP2846787B1/en active Active
- 2013-05-08 ES ES13788050T patent/ES2699646T3/es active Active
-
2014
- 2014-11-05 IL IL235512A patent/IL235512B/en active IP Right Grant
-
2015
- 2015-06-27 US US14/752,839 patent/US9573885B2/en active Active
- 2015-09-17 HK HK15109093.0A patent/HK1208363A1/xx unknown
-
2017
- 2017-10-31 JP JP2017210529A patent/JP6570597B2/ja active Active
-
2018
- 2018-05-14 AU AU2018203357A patent/AU2018203357C1/en active Active
- 2018-05-17 US US15/982,644 patent/US11084778B2/en active Active
-
2021
- 2021-07-26 US US17/443,361 patent/US11873266B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250690A1 (zh) | 方法 | |
HK1208363A1 (en) | New methods | |
EP2836211A4 (en) | NOVEL PROCEDURE | |
DK3327112T3 (en) | Agse-deficient stamme | |
EP2754580A4 (en) | DUMP TRUCK | |
DK2830816T3 (en) | Hidtil ukendt coatingkoncept | |
EP2920142A4 (en) | MÉTHANOFULLERRÈNES | |
GB2507760B (en) | Methods | |
EP2812698A4 (en) | TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR | |
GB201208874D0 (en) | Methods | |
EP2920157A4 (en) | DI MACRO CYCLEN | |
EP2873363A4 (en) | DIOPSIMETER | |
GB201204280D0 (en) | Methods | |
EP2834250A4 (de) | Lithiumsilikate | |
GB201208756D0 (en) | Methods | |
GB201220686D0 (en) | Methods | |
AP2012000550S (en) | E-horn methods | |
GB201216074D0 (en) | Methods | |
GB201209689D0 (en) | Methods | |
GB201208963D0 (en) | Methods | |
GB201208875D0 (en) | Methods | |
GB201207793D0 (en) | Methods | |
AU345893S (en) | Treehouse | |
GB201211957D0 (en) | SqueezMe | |
GB201210111D0 (en) | Giggsters |